Patents by Inventor Anna Wald

Anna Wald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HERPES SIMPLEX VIRUS VACCINE EPITOPES SPECIFICALLY RECOGNIZED BY TISSUE RESIDENT MEMORY T CELLS
    Publication number: 20200164060
    Abstract: Herpes Simplex Virus type 2 (HSV-2) epitopes bound by CD8 or CD4 tissue resident memory cells at a healed site of HSV-2 infection are disclosed. The HSV-2 epitopes can be used as immunogenic compositions to elicit protective immune responses against HSV-2.
    Type: Application
    Filed: July 20, 2018
    Publication date: May 28, 2020
    Applicants: Fred Hutchinson Cancer Research Center, University of Washington
    Inventors: David Koelle, Anna Wald, Christine Johnston, Christine Posavad, Larry Corey
  • Antigenic peptide of HSV-2 and methods for using same
    Patent number: 9579376
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: February 28, 2017
    Assignees: UNIVERSITY OF WASHINGTON, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Lawrence Corey, Kerry J. Laing, Anna Wald, David M. Koelle
  • EPITOPES CROSS-REACTIVE BETWEEN HSV-1, HSV-2 AND VZV AND METHODS FOR USING SAME
    Publication number: 20170049881
    Abstract: The invention provides epitopes of HSV and VZV that are cross-reactive and are useful for the prevention and treatment of alphaherpesvirus infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against whole virus. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing epitopes or polynucleotides encoding epitopes of the invention provide effectively targeted vaccines for prevention and treatment of alphaherpesvirus infection.
    Type: Application
    Filed: May 1, 2015
    Publication date: February 23, 2017
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: David M. KOELLE, Lichen JING, Kerry LAING, Christine JOHNSTON, Anna WALD
  • ANTIGENIC PEPTIDE OF HSV-2 AND METHODS FOR USING SAME
    Publication number: 20150335734
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Application
    Filed: June 1, 2015
    Publication date: November 26, 2015
    Applicants: FRED HUTCHINSON CANCER RESEARCH CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Lawrence Corey, Kerry J. Laing, Anna Wald, David M. Koelle
  • Antigenic peptide of HSV-2 and methods for using same
    Patent number: 9044447
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Grant
    Filed: April 3, 2010
    Date of Patent: June 2, 2015
    Assignees: UNIVERSITY OF WASHINGTON, FRED HUTCHISON CANCER RESEARCH CENTER
    Inventors: Lawrence Corey, Kerry J. Laing, Anna Wald, David M. Koelle
  • ANTIGENIC PEPTIDE OF HSV-2 AND METHODS FOR USING SAME
    Publication number: 20120027789
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV, The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Application
    Filed: April 3, 2010
    Publication date: February 2, 2012
    Applicants: Fred Hutchinson Cancer Research Center, University of Washington
    Inventors: Lawrence Corey, Kerry J. Laing, Anna Wald, David M. Koelle